{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=80",
    "query": {
      "intervention": "Part 3",
      "page": 80
    },
    "page_size": 10
  },
  "pagination": {
    "page": 80,
    "page_size": 10,
    "total_count": 4023,
    "total_pages": 403,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=81&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=79&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T15:54:52.281Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04395092",
      "title": "Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Myelodysplastic Syndromes (MDS)"
      ],
      "interventions": [
        {
          "name": "K-NK002",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Conditioning Regimen",
          "type": "PROCEDURE"
        },
        {
          "name": "HaploBMT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Kiadis Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-11-13",
      "completion_date": "2023-11",
      "has_results": false,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-11-12T15:54:52.281Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Houston, Texas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04395092"
    },
    {
      "nct_id": "NCT00546871",
      "title": "Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency Diseases (PID)"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous (Human), 10%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "24 Months and older"
      },
      "enrollment_count": 49,
      "start_date": "2007-10-03",
      "completion_date": "2009-09-01",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-11-12T15:54:52.281Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546871"
    },
    {
      "nct_id": "NCT02603432",
      "title": "A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "Avelumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Best Supportive Care",
          "type": "OTHER"
        },
        {
          "name": "Following the planned interim analysis for this study: Avelumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2016-04-25",
      "completion_date": "2023-03-28",
      "has_results": true,
      "last_update_posted_date": "2024-03-27",
      "last_synced_at": "2026-11-12T15:54:52.281Z",
      "location_count": 19,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02603432"
    },
    {
      "nct_id": "NCT01828034",
      "title": "First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Biliary Tract Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "MEK162",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2013-04",
      "completion_date": "2019-05-30",
      "has_results": true,
      "last_update_posted_date": "2020-11-17",
      "last_synced_at": "2026-11-12T15:54:52.281Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01828034"
    },
    {
      "nct_id": "NCT06026124",
      "title": "Retrieval-Based Word Learning in Developmental Language Disorder During Book Reading",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Developmental Language Disorder",
        "Specific Language Impairment",
        "Language Development"
      ],
      "interventions": [
        {
          "name": "Retrieval-based word learning: Repeated Spaced Retrieval condition",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Retrieval-based word learning: Repeated Study condition",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Purdue University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "48 Months",
        "maximum_age": "71 Months",
        "sex": "ALL",
        "summary": "48 Months to 71 Months"
      },
      "enrollment_count": 27,
      "start_date": "2022-10-31",
      "completion_date": "2024-09-17",
      "has_results": true,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-11-12T15:54:52.281Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • West Lafayette, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "West Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06026124"
    },
    {
      "nct_id": "NCT05121142",
      "title": "Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute-graft-versus-host Disease",
        "Chronic Graft-versus-host-disease",
        "Solid Organ Transplant"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 13,
      "start_date": "2021-10-27",
      "completion_date": "2023-05-13",
      "has_results": false,
      "last_update_posted_date": "2024-01-16",
      "last_synced_at": "2026-11-12T15:54:52.281Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05121142"
    },
    {
      "nct_id": "NCT00976261",
      "title": "A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "GSK1614235",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "30 Years to 65 Years"
      },
      "enrollment_count": 72,
      "start_date": "2009-10-17",
      "completion_date": "2010-09-05",
      "has_results": false,
      "last_update_posted_date": "2017-06-08",
      "last_synced_at": "2026-11-12T15:54:52.281Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Baton Rouge, Louisiana • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00976261"
    },
    {
      "nct_id": "NCT01146574",
      "title": "A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Sotatercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2010-06-30",
      "completion_date": "2016-03-07",
      "has_results": true,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-11-12T15:54:52.281Z",
      "location_count": 24,
      "location_summary": "Azusa, California • Glendale, California • La Mesa, California + 16 more",
      "locations": [
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01146574"
    },
    {
      "nct_id": "NCT05367596",
      "title": "OPTIMIzing muScle Preservation in paTients wIth Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Compensated Cirrhosis",
        "Sarcopenia"
      ],
      "interventions": [
        {
          "name": "Continuous Energy Restriction (CER)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Alternate Day Modified Fasting (ADMF)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Group Health Education Sessions",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Late Evening Snack",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Physical activity",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Self-monitoring",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Remotely Supervised Exercise Sessions",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-06-22",
      "completion_date": "2022-12-16",
      "has_results": false,
      "last_update_posted_date": "2023-02-09",
      "last_synced_at": "2026-11-12T15:54:52.281Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05367596"
    },
    {
      "nct_id": "NCT04580797",
      "title": "Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "PF-06700841 IR",
          "type": "DRUG"
        },
        {
          "name": "PF-06700841 MR1",
          "type": "DRUG"
        },
        {
          "name": "PF-06700841 MR2",
          "type": "DRUG"
        },
        {
          "name": "PF-06700841 MR3",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2020-10-02",
      "completion_date": "2021-01-11",
      "has_results": false,
      "last_update_posted_date": "2021-03-08",
      "last_synced_at": "2026-11-12T15:54:52.281Z",
      "location_count": 2,
      "location_summary": "Coral Gables, Florida • Miami, Florida",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04580797"
    }
  ]
}